All News

Found 809 articles

• LinusBio Raises $16 Million to Scale Growth and Deliver Tangible Outcomes

  1/12/2023

  LinusBio , a leader in precision exposome sequencing, today announced it raised over $16 million in Series A funding to deliver a novel platform that bridges genomics, the environment, and biological response.

• SOPHiA GENETICS and Leading US Cancer Center Collaborate to Combine Cancer Analysis Technology for Liquid Biopsies

  1/10/2023

  SOPHiA GENETICS™ (Nasdaq: SOPH), a cloud-native software company in the healthcare space, has entered an agreement with Memorial Sloan Kettering Cancer Center (MSK) to offer clinicians and researchers new solutions to expand their testing and analytical capabilities.

• PrognomiQ's Multi-omics Liquid Biopsy Platform Demonstrates Promising Results in Early-Stage Cancer Detection of Non-Small Cell Lung Cancer

  1/9/2023

   PrognomiQ today announced the achievement of early results from the largest, deep multi-omics study, demonstrating the power of diverse molecular biomarkers to improve sensitivity and specificity in the early detection of cancer.

• IONIQ Sciences to Present at Biotech Showcase

  1/5/2023

  ProLung, Inc. dba IONIQ Sciences, Inc. announced it is presenting in person at Biotech Showcase™, the investor conference for innovators.

• FoundationOne®Liquid CDx Receives FDA Approval as a Companion Diagnostic for Rozlytrek® (entrectinib)

  1/4/2023

  Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne®Liquid CDx to be used as a companion diagnostic to identify patients with ROS1-positive non-small cell lung cancer (NSCLC), or patients with NTRK fusion-positive solid tumors, who do not have a tissue sample available and may be appropriate for treatment with Rozlytrek (entrectinib).

• US FDA Grants Breakthrough Designation for Blood Test to Help Diagnose Inaccessible Brain Tumors

  1/2/2023

  Datar Cancer Genetics Inc announced that the US Food and Drug Administration has granted 'Breakthrough Device Designation' for its 'TriNetra™-Glio', a blood test to help in the diagnosis of brain tumors.

• Insightec Announces Milestone of First Patients Enrolled in the Pivotal LIBERATE Clinical Trial (Liquid Biopsy with Low Intensity Ultrasound in Brain Tumors)

  12/15/2022

  Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, announced today the first patients have enrolled in the pivotal LIBERATE clinical trial (Liquid Biopsy with Low Intensity Ultrasound in Brain Tumors).

• Agilent Resolution ctDx FIRST Receives FDA Approval as a Liquid Biopsy Companion Diagnostic Test for Advanced Non-small Cell Lung Cancer

  12/13/2022

  Agilent Technologies Inc. announced that the U.S. Food and Drug Administration has approved Agilent Resolution ctDx FIRST as a companion diagnostic to identify advanced non-small cell lung cancer patients with KRAS G12C mutations who may benefit from treatment with KRAZATITM.

• Telo Genomics Appoints Kris Weinberg as Chief Executive Officer

  12/12/2022

  Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce the appointment of Kris Weinberg as Chief Executive Officer ("CEO"), effective today. Telo Genomics' current CEO, Sherif Louis PhD, will assume the position of President & Chief Technology Officer.

• Sermonix Shares Two Posters at SABCS 2022 on ER+/HER2- Metastatic Breast Cancer Patient Survey About Knowledge of NGS and ESR1 Mutations, Quality of Life Concerns

  12/9/2022

  Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, shared two poster presentations at the 2022 San Antonio Breast Cancer Symposium evaluating the results of an online survey of ER+/HER2- metastatic breast cancer patients.

• Telo Genomics Forms World-Class Multiple Myeloma Advisory Board in Preparation for the American Society of Hematology Annual Meeting

  12/8/2022

  Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce the formation of a multiple myeloma advisory board ("MM Advisory Board").

• Genomic Testing Cooperative to Present Data at the American Society of Hematology Meeting on New Applications of its Proprietary Tests that Combine Transcriptome Data Obtained from Tissue or Liquid Biopsies with Machine Learning

  12/6/2022

  Genomic Testing Cooperative, LCA (GTC) announced the presentation of four innovative studies at the annual American Society of Hematology (ASH) meeting that will be held from December 10 to 13, 2022 in New Orleans, Louisiana.

• Cancer Diagnostics Market Size to Reach USD 293.8 BN by 2030

  12/6/2022

  According to Nova one advisor, the global Cancer Diagnostics market size was valued at USD 160.9 billion in 2021 and is predicted to hit USD 293.8 billion by 2030 with a registered CAGR of 6.90% during the forecast period 2022 to 2030.

• Prominent oncologist to discuss advantages of Oxford BioDynamics’ EpiSwitch CiRT at the 2022 Liquid Biopsy Virtual Summit

  11/21/2022

  Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch 3D genomics platform, announces that prominent medical oncologist, Dr. Steven Mamus, a regular user of EpiSwitch CiRT, will be speaking about OBD’s flagship test at the 2022 Liquid Biopsy Virtual Summit, 6 December 2022.

• Cancer Biomarkers Market Size - Quantitative Research By QYResearch Medical

  11/17/2022

  The global cancer biomarkers market size was USD 27.83 Billion in 2021, and is expected to register a revenue CAGR of 17.6% during the forecast period.

• Novozymes and LinusBio announce collaboration to accelerate scientific discovery in Biohealth

  11/10/2022

  Novozymes, the world leader in biological solutions, and LinusBio, a leader in precision exposome sequencing, announced the companies are forming a collaboration to test a new, non-invasive technology in a clinical trial.

• Telo Genomics Launches a Minimal Residual Disease Clinical Trial in Multiple Myeloma

  11/9/2022

  Toronto, Ontario--(Newsfile Corp. - November 9, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce today that it is launching a clinical trial to monitor multiple myeloma disease progression in post-treated patients, by measuring and profiling the minimal residual disease ("MRD") in these patients.

• Cancer Diagnostics Market Size to Hit Around USD 293.8 BN by 2030

  10/27/2022

  According to Nova one advisor, the global Cancer Diagnostics market size was valued at USD 160.9 billion in 2021 and is predicted to hit USD 293.8 billion by 2030 with a registered CAGR of 6.90% during the forecast period 2022 to 2030.

• HTG to Collaborate With OmiCure, Providing Transcriptomic Data Across Several Cancer Indications

  10/26/2022

  HTG Molecular Diagnostics, Inc. and OmiCure® announced a collaboration with OmiCure to implement the HTG Transcriptome Panel as an alternative to RNA-Seq to inform the OmiCure test and help guide therapeutic decision-making across several cancer types.

• IONIQ Sciences to Present at BioFuture

  10/24/2022

  ProLung, Inc. dba IONIQ Sciences, Inc. today announced it is presenting at BioFuture and also providing an on-demand company presentation.